Enterprise Value

622.7M

Cash

131.1M

Avg Qtr Burn

-65.48M

Short % of Float

27.43%

Insider Ownership

1.33%

Institutional Own.

79.08%

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
UDENYCA® ONBODY Details
Cancer, Chemotherapy-induced neutropenia

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

CIMERLI (CHS-201) (Lucentis biosimilar) Details
Wet age-related macular degeneration , Age-related macular degeneration, Eye disease

Approved

Quarterly sales

UDENYCA® (pegfilgrastim-cbqv) Biosimilar Details
Cancer, Chemotherapy-induced neutropenia

Approved

Quarterly sales

Phase 3

Update

LOQTORZI (Toripalimab) + INO 3112 Details
HPV+ oropharyngeal cancer, Cancer

Phase 3

Initiation

Phase 2

Update

Casdozokitug (casdozo) Details
Cancer, Non-small cell lung carcinoma

Phase 1/2

Data readout

Toripalimab +/- CHS-006 (anti-TIGIT) (anti-PD-1) Details
Solid tumor/s, Non-small cell lung carcinoma, Hepatocellular carcinoma

Phase 1/2

Data readout

CHS-131 Details
Multiple sclerosis, Non-alcoholic steatohepatitis

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued